Bain Capital Life Sciences Investors, LLC CCCC — C4 THERAPEUTICS, INC.

Ownership history in Bain Capital Life Sciences Investors, LLC  ·  22 quarters on record

AI Ownership Summary

Bain Capital Life Sciences Investors, LLC reported C4 THERAPEUTICS, INC. (CCCC) in 22 quarterly 13F filings from 2024 Q1 through 2026 Q1. Peak portfolio weight reached 1.7% in 2026 Q1. The latest visible filing shows CCCC at 1.70% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this CCCC ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Bain Capital Life Sciences Investors, LLC's position in C4 THERAPEUTICS, INC., and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

CCCC was reported at 1.70% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
1.7% in 2026 Q1

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

CCCC stock page Bain Capital Life Sciences Investors, LLC fund profile Bain Capital Life Sciences Investors, LLC full holdings
How Bain Capital Life Sciences Investors, LLC held CCCC — position size vs. price
% of Fund (quarterly)    CCCC price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 9 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 UNCHANGED — — — 7,171,910 — 0% 1.70% $18.9M 2026-05-15 $3.56
2025 Q4 ADDED — — — 7,171,910 +6,060,000 +545.0% 1.05% $13.7M 2026-02-17 $1.83
2025 Q3 UNCHANGED — — — 1,111,910 — 0% 0.16% $2.5M 2025-11-14 $2.47
2025 Q2 UNCHANGED — — — 1,111,910 — 0% 0.20% $1.59B 2025-08-14 $2.35
2025 Q1 UNCHANGED — — — 1,111,910 — 0% 0.26% $1.78B 2025-05-15 $1.38
2024 Q4 UNCHANGED — — — 1,111,910 — 0% 0.47% $4.00B 2025-02-14 $3.18
2024 Q3 UNCHANGED — — — 1,111,910 — 0% 0.66% $6.3M 2024-11-14 $4.72
2024 Q2 REDUCED — — — 1,111,910 -30,300 -2.7% 0.56% $5.1M 2024-08-12 $5.72
2024 Q1 REDUCED 30.4% -40.6% ✅ 1,142,210 -500,000 -30.4% 0.75% $9.3M 2024-05-15 $6.11
13 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding CCCC

As of 2026 Q1 — sorted by position size

Lynx1 Capital Management LP 3Y 2.91% Squadron Capital Management LLC 2.17% SILVERARC CAPITAL MANAGEMENT, LLC 3Y 0.51% Soleus Capital Management, L.P. 3Y 0.41% Verdad Advisers, LP 3Y 0.32% PLATINUM INVESTMENT MANAGEMENT LTD 3Y 7Y 0.26% STEMPOINT CAPITAL LP 0.23% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 0.22% INTREPID FAMILY OFFICE LLC 3Y 0.13% Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group 0.09%

FAQ About Bain Capital Life Sciences Investors, LLC and CCCC

These are the practical questions this page is built to answer before you even open the full history table.

How long has Bain Capital Life Sciences Investors, LLC reported owning CCCC?

Bain Capital Life Sciences Investors, LLC reported CCCC across 9 quarterly 13F filings, from 2024 Q1 through 2026 Q1.

What was the largest reported CCCC position in Bain Capital Life Sciences Investors, LLC's portfolio?

The largest reported portfolio weight for CCCC was 1.70% in 2026 Q1.

What is the latest reported CCCC position on this page?

The most recent filing on this page is 2026 Q1, when Bain Capital Life Sciences Investors, LLC reported 7,171,910 shares, equal to 1.70% of portfolio, with an estimated market value of $18.9M.

What does the chart on this CCCC ownership page compare?

The chart compares Bain Capital Life Sciences Investors, LLC's quarterly CCCC portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Bain Capital Life Sciences Investors, LLC time their CCCC position?

Based on 13F filing dates vs. subsequent CCCC price moves, Bain Capital Life Sciences Investors, LLC correctly timed 3 out of 5 reported position changes (60%). The annualised alpha on CCCC relative to SPY over the holding period was -45.2%.

← Back to Bain Capital Life Sciences Investors, LLC Holdings